Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis

British Journal of Haematology

Volumn 112, Issue 1, 2001, Pages 228-236

  Craddock, C ^a   Szydlo, R M ^a   Dazzi, F ^a   Olavarria, E ^a   Cwynarski, K ^a   Yong, A ^a   Brookes, P ^a   De La Fuente, J ^a   Kanfer, E ^a   Apperley, J F ^a   Goldman, J M ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bone marrow transplantation; Chronic myeloid leukaemia; Cytomegalovirus; Unrelated donor

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; GANCICLOVIR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; SEROLOGY; STATISTICAL ANALYSIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PROBABILITY; SURVIVAL RATE; TISSUE DONORS;

EID: 0035133203     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02519.x     Document Type: Article

References (46)

1. CMV-antigenemia after allogeneic bone marrow transplantation: Correlation of CMV-antigen positive cell numbers with transplant-related mortality
2. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus
3. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains
4. Increased transplant related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
5. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia
6. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies
7. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia after bone marrow transplantation
8. A comparison of single dose and escalating dose regimens of donor lymphocyte infusion for patients who relapse after allografting for chronic myeloid leukemia
9. 8/Kg)
10. Effect of T-cell depletion as graft versus-host disease prophylaxis on engraftment, relapse and disease free survival in unrelated marrow transplantation for chronic myelogenous leukemia
11. Relapse after non T cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Early transplantation, use of an unrelated donor and chronic graft versus host disease are protective
12. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: No evidence of increased incidence in patients receiving unrelated donor grafts
13. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
14. Bone marrow transplantation for patients with chronic myeloid leukemia
15. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associate with T-cell depletion
16. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
17. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
18. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
19. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course to active cytomegalovirus infection and disease after BMT
20. Nonparametric estimation from incomplete observations
21. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
22. Cytomegalovirus viremia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation
23. Bone marrow transplantation for chronic myeloid leukemia: The use of histocompatible unrelated volunteer donors
24. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia effect from graft-versus-host disease
25. Allogeneic bone marrow transplantation for chronic myeloid leukaemia using sibling and volunteer unrelated donors: A comparison of complications in the first two years
26. Graft failure in patients receiving T cell depleted HLA-identical allogeneic marrow Transplants
27. Evaluation of the mixed lymphocyte culture assay (MLC) as a method for selecting unrelated donors for marrow transplantation
28. Late infections after allogeneic bone marrow transplantation: Comparison of incidence in related and unrelated donor transplant recipients
29. Measurement of cytotoxic T lymphocyte precursor frequencies reveals cryptic HLA class I mismatches in the context of unrelated donor
30. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
31. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1
32. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation
33. Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection
34. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program
35. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome positive CML in first chronic phase
36. Comparative outcomes of T-cell-depleted and non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion
37. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA matching and marrow cell dose
38. Allogeneic bone marrow transplantation for chronic myeloid leukaemia
39. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient
40. Cytotoxic T lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors
41. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
42. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings
43. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation
44. Marrow transplantation for the treatment of chronic myelogenous leukemia
45. Ganciclovir and the prevention of CMV disease after allogeneic BMT: The policy at the Hammersmith Hospital
46. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection